Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.53 |
| ▸ | SLC34A1 | Q06495 | 6/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314951 | 0.82 | PDE4D (1.00) | PDE4DMAPTPDE4BSLC34A1P2RY12 | |
| SCHEMBL6070203 | 0.81 | PDE4D (0.63) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL123446 | 0.80 | PDE4D (0.67) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL3269737 | 0.77 | PDE4D (0.56) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL15167787 | 0.75 | MAPT (0.68) | PDE4DKDM4EMAPTSLC34A1NPC1 | |
| SCHEMBL6070211 | 0.75 | PDE4D (0.73) | PDE4DMAPTPDE4BP2RY12NPC1 | |
| SCHEMBL6070491 | 0.74 | PDE4B (0.73) | PDE4DKDM4EMAPTPDE4BP2RY12 | |
| SCHEMBL6070100 | 0.74 | KDM4E (0.62) | PDE4DKDM4EMAPTPDE4BSLC34A1 | |
| SCHEMBL13920725 | 0.73 | LMNA (0.43) | PDE4DKDM4EMAPTNPC1RAB9A | |
| SCHEMBL6070059 | 0.73 | PDE4D (0.80) | PDE4DMAPTPDE4BSLC34A1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | PDE4D 1187/4885KDM4E 2664/4885MAPT 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.